CACanada
Mounjaro cardiovascular indication approved by Health Canada after a head to head trial with Trulicity
Health Canada has approved tirzepatide to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes and heart disease. The pivotal trial showed it was not worse than dulaglutide, but did not prove it better.
Illustration by Peptide Global, not a picture of the place in the story.
The short of itHealth Canada approved Mounjaro to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, based on the SURPASS-CVOT trial against dulaglutide.
Health Canada has added a Mounjaro cardiovascular indication for adults with type 2 diabetes and established heart or blood vessel disease, Eli Lilly Canada said on 18 November. The regulator issued a Notice of Compliance that lets tirzepatide be used to lower the risk of major cardiovascular events, meaning cardiovascular death, non fatal heart attack or non fatal stroke. The decision rests on SURPASS-CVOT, a trial that pitted tirzepatide against another incretin drug rather than a placebo. The result showed tirzepatide was not worse than its comparator, which is a narrower finding than the company's headline suggests.
What Health Canada approved
Until now Mounjaro was approved in Canada only to improve blood sugar control, used with diet and exercise, in adults and in children aged 10 and older with type 2 diabetes. The new Notice of Compliance adds a second purpose for adults whose diabetes comes with established cardiovascular disease: reducing the chance of a first major cardiovascular event. Lilly Canada announced the change from Toronto in a company release and described Mounjaro as the first and only dual GIP and GLP-1 receptor agonist shown to lower these events in this group. That claim is the company's own. Health Canada does not publish a press release for each Notice of Compliance, and the updated product monograph is the document that sets the exact wording for prescribers.
The step brings Canada in line with the United States, where the Food and Drug Administration approved a similar use of tirzepatide in late August, according to a Pharmacy Times report. Canadian doctors already had GLP-1 drugs with heart claims. Lilly's own release notes that Trulicity, the brand name of dulaglutide, is approved in Canada to reduce the risk of non fatal stroke in people with type 2 diabetes who have established cardiovascular disease or several risk factors. What changes is that a dual agonist, which acts on two gut hormone receptors and which Lilly says lowers A1C and weight more than semaglutide in direct comparison, now carries its own outcome claim. The release did not say whether the label wording differs from the American version.
What the SURPASS CVOT trial found
SURPASS-CVOT enrolled more than 13,000 adults with type 2 diabetes and established cardiovascular disease in 30 countries, Canada among them, and followed them for more than four and a half years, Lilly said. It was the first cardiovascular outcomes trial to compare two incretin drugs directly. Tirzepatide was set against dulaglutide, a drug with a proven heart benefit, so the main question was whether tirzepatide was at least as good. The rate of the combined outcome of cardiovascular death, heart attack or stroke was 8 percent lower with tirzepatide. The hazard ratio was 0.92, with a 95.3 percent confidence interval running from 0.83 to 1.01, the company reported.
Because the upper end of that interval crosses 1, the trial met its test for non inferiority but did not prove that tirzepatide is better than dulaglutide.
Because the upper end of that interval crosses 1, the trial met its test for non inferiority but did not prove that tirzepatide is better than dulaglutide. A summary by the American College of Cardiology of the paper in The New England Journal of Medicine reports the same split: the non inferiority test passed, while the test for superiority did not reach statistical significance. The primary event occurred in about 12 percent of tirzepatide patients and 13 percent of dulaglutide patients over a median follow up of about four years. Lilly's release says the result demonstrated a cardiovascular benefit. Read carefully, the trial shows tirzepatide protects the heart at least as well as an established drug while doing more for blood sugar and weight.
The Mounjaro cardiovascular indication in practice
For Canadian prescribers, the Mounjaro cardiovascular indication matters most for patients who need both strong glucose control and protection after a heart attack or stroke. Dr Jeffrey Habert, a family doctor and assistant professor at the University of Toronto, said in the release that managing type 2 diabetes "means looking beyond A1C" and called the approval "an important advance for patients and for primary care." Dr Harpreet Bajaj, the Canadian national lead investigator of the trial, said the evidence "gives us another important option." Mathilde Merlet, president and general manager of Lilly Canada, said the indication builds on the drug's blood sugar and weight effects. The trial was run by Lilly, and all three comments come from Lilly.
| Item | Detail |
|---|---|
| Regulator | Health Canada, Notice of Compliance |
| Announced | 18 November 2026 by Eli Lilly Canada |
| Medicine | Mounjaro, tirzepatide, dual GIP and GLP-1 receptor agonist |
| New use | Lower the risk of cardiovascular death, non fatal heart attack or non fatal stroke |
| Patients | Adults with type 2 diabetes and established cardiovascular disease |
| Pivotal trial | SURPASS-CVOT, more than 13,000 participants in 30 countries |
| Comparator | Dulaglutide (Trulicity) |
| Hazard ratio | 0.92, 95.3 percent confidence interval 0.83 to 1.01 |
| Superiority over dulaglutide | Not shown |
Safety in the trial was broadly in line with what was already known for the drug, Lilly said. The most common side effects were gastrointestinal, mostly mild to moderate, and they occurred mainly while the dose was being stepped up. The release did not give rates of stopping treatment or of serious adverse events, and the full figures sit in the journal paper and the Canadian product monograph. The approval does not cover weight management or people without diabetes, and nothing in the announcement changes how the drug is started. The new wording mainly affects how doctors weigh the drug against other options for patients who have already had a heart attack, a stroke or other vascular disease.
What to watch in Canada
Coverage is the first open question. The release did not mention public drug plans or private insurers, and a new indication does not by itself change who pays. Provincial formularies and employer plans set their own criteria for diabetes drugs, and they may or may not treat the heart claim as a reason to widen access. The second is competition. Generic semaglutide is arriving in Canada, and this site has reported that Indian generic semaglutide makers are targeting the Canadian market. Cheaper semaglutide copies would give payers a lower priced incretin to set against tirzepatide, which has no copies on the Canadian market.
The third question is supply and safety outside normal channels. Health Canada has been active against unlicensed injectables, and its recent seizure of peptide vials found bacteria in some products. Broader approved uses for brand medicines tend to raise demand, and with it the incentive for sellers of copies outside the legal supply chain. Patients should get tirzepatide only through a prescriber and a licensed pharmacy. For the wider story, the Canadian decision is one of several regulators acting on the same trial within months. Further approvals for the heart indication in other markets, and any head to head data against semaglutide on hard outcomes, are the next items to follow.
Conclusion
Health Canada's Notice of Compliance gives Mounjaro a cardiovascular indication for adults with type 2 diabetes and established cardiovascular disease, based on SURPASS-CVOT. The trial showed tirzepatide was not inferior to dulaglutide, with an 8 percent lower event rate that fell short of proving superiority. The Mounjaro cardiovascular indication now matches the American label in purpose, while coverage decisions and the arrival of generic semaglutide will shape how much it changes Canadian prescribing.
Why it matters in Canada
Canadian doctors gain a dual GIP and GLP-1 drug with its own heart outcome claim just as generic semaglutide enters the market, so payers and prescribers will compare the two on price and evidence.
What to watch
Whether provincial drug plans and private insurers change coverage criteria, how generic semaglutide pricing affects tirzepatide, and approvals of the heart indication in other markets.
Sources
Spotted a wrong figure? Tell the desk; we fix errors under our corrections policy.
Peptide Global reports news about medicines and markets. Nothing here is medical or investment advice.